Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

IntroductionThe standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by consolidation durvalumab as shown in the PACIFIC trial. The purpose of this study is to evaluate clinical outcomes and toxicities regarding the use of d...

Descripció completa

Dades bibliogràfiques

Autors principals:	Paolo Borghetti, Giulia Volpi, Giorgio Facheris, Gianluca Cossali, Eneida Mataj, Salvatore La Mattina, Navdeep Singh, Jessica Imbrescia, Marco Lorenzo Bonù, Davide Tomasini, Paola Vitali, Diana Greco, Michela Bezzi, Flavia Melotti, Mauro Benvenuti, Andrea Borghesi, Salvatore Grisanti, Michela Buglione di Monale e Bastia
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-07-01
Col·lecció:	Frontiers in Oncology
Matèries:	non-small cell lung cancer (NSCLC) stage III durvalumab chemo-radiotherapy (CRT) real-world data (RWD)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1208204/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!